Ionis Pharmaceuticals (IONS) Tops Q2 EPS by 94c ; Offers Guidance

Ionis Pharmaceuticals (NASDAQ: IONS) reported Q2 EPS of $0.70, $0.94 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $452 million versus the consensus estimate of $286.01 million.

GUIDANCE:

Ionis Pharmaceuticals sees FY2025 revenue of $825-850 million, versus the consensus of $755.8 million.

For earnings history and earnings-related data on Ionis Pharmaceuticals (IONS) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• TEOCO selects Strategy One platform for telecom invoice analytics